According to police officials in Puducherry, the accused were manufacturing and distributing counterfeit medicines bearing Lupin branding. A First Information Report (FIR) has been registered under provisions of the Drugs and Cosmetics Act following the seizure of falsified pharmaceutical products and packaging materials. Officials confirmed that the seized items were designed to resemble genuine Lupin medicines.
How Fake Medicines Enter the Supply Chain
The pharmaceutical industry relies on a structured pharmaceutical supply chain that moves medicines from manufacturers through distributors before reaching pharmacies and patients. Authorities stated that the counterfeit products closely mimicked authentic Lupin medicines, including labels and packaging, making drug authentication difficult once the products entered informal distribution channels.
The case demonstrates how gaps in supply chain management and limited supply chain visibility can allow fake medicines to pass undetected until discovered by law enforcement.
Gaps in Supply Chain Management and Traceability
Officials noted that counterfeit drug operations exploit weaknesses in supply chain traceability and inadequate medicine traceability systems. Without reliable supply chain software or end-to-end tracking mechanisms, enforcement agencies often identify counterfeit medicines only after they have already entered the market.
The seizure in Puducherry highlights the challenges regulators face when supply chain transparency is limited and product movement cannot be easily verified across distribution points.
Enforcement Action and Public Health Risk
Police confirmed that the operation involved the illegal production and circulation of falsified medicines using Lupin branding. Such cases pose serious risks to public health, as fake medicines may contain incorrect or harmful substances and bypass regulatory quality controls.
Authorities emphasized that continued vigilance and stronger oversight are required to prevent counterfeit medicines from entering the pharmaceutical supply chain.
A Technology-Enabled Path Forward
While the Puducherry case reflects a law-enforcement action, it also underscores the need for stronger drug traceability mechanisms within the pharmaceutical industry.
Platforms such as Synchrypt are designed to address these gaps by enabling medicine serialization, drug authentication, and end-to-end supply chain traceability using blockchain technology. By creating tamper-resistant records across the pharmaceutical supply chain, such systems can help manufacturers, regulators, and distributors detect anomalies earlier and reduce the circulation of counterfeit medicines.
Source:
Medical Dialogues — Counterfeit Drug Racket Using Lupin Brand Busted in Puducherry